Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
everything can happen-The company is scheduled to release its earnings on November 2, 2023. The company is predicted to post an EPS of -$1.80, indicating a 171.15% decline compared to the equivalent quarter last year. Meanwhile, the latest consensus estimate predicts the revenue to be $1.36 billion, indicating a 59.47% decrease compared to the same quarter of the previous year.
It is early to say, only time will tell- money machine-
:-Moderna's valuation can be difficult to gauge. You can't truly rely on earnings on revenue multiples, as the business is going to look a lot different as it transitions to other products. It's currently trading at only 3 times its trailing revenue. But if the company's sales fall further, then that sales multiple will quickly rise. Plus, declining revenue will put pressure on its bottom line.
mRNA-1647: a vaccine for cytomegalovirus, which could generate peak sales between $2 billion and $5 billion.
mRNA-1345: a vaccine for respiratory syncytial virus, which may bring in over $2 billion in peak annual sales.
mRNA-1893: a vaccine for Zika virus that could be worth hundreds of millions of dollars.
A bit of a longer shot is the company's cancer vaccine, mRNA-4157, that it is working on with Merck
the work continues_ Moderna, meanwhile, is working with Big Pharma Merck & Co., known as MSD here in Spain, on a personalized cancer vaccine called mRNA-4157 that is soon to enter phase 3. While the companies didn’t have major news to reveal at ESMO, both had a presence.
ESMO: Moderna, BioNTech's post-COVID futures in oncology hit manufacturing realities
https://www.fiercepharma.com/manufacturing/moderna-biontechs-post-covid-futures-oncology-hit-manufacturing-realities
Let us move forward towards a new future$
Caris Life Sciences and Moderna Announce Multi-Year Strategic Partnership to Advance mRNA-Based Oncology Therapeutics
https://finance.yahoo.com/news/caris-life-sciences-moderna-announce-103000173.html
Moderna Announces First Participant Dosed in Phase 3 Study of mRNA-1083, a Combination Vaccine Against Influenza and COVID-19
https://investors.modernatx.com/news/news-details/2023/Moderna-Announces-First-Participant-Dosed-in-Phase-3-Study-of-mRNA-1083-a-Combination-Vaccine-Against-Influenza-and-COVID-19/default.aspx
is a fight against ignorance...let's see what happens
he was a godsend less than $80>>>>>>>>>>
" updates coming soon" On October 23rd, Dr. Jeffrey S. Weber we will be presenting clinical results and treatment outcomes from our Phase 2b KEYNOTE-942/mRNA-4157-P201 trial. cancer
IH- you only live once.....relax baby
I THINK WHITE YOU THINK BLACK ....freedom of thought
the world moves forward anyway..no problem$$$$$$
time will tell-Breast cancer vaccine trial gives new hope to patients https://www.fox29.com/video/1294611
IH- time will tell. Ohio-native Jennifer Davis received her last dose in 2021 and is still cancer-free
Now, the researchers have set their sights on recruiting women who have never had triple-negative cancer but are at higher risk in a bid to see if the vaccine could prevent the cancer from attacking in the first place.
questions to shift to a new future....
‘I Was The First Person To Get The New Breast Cancer Vaccine—And It Completely Changed My Life’https://t.co/KOTsaZn7s7 pic.twitter.com/af4qCcCVvD
— Anixa Biosciences (@AnixaBio) October 9, 2023
IH_ the twisted mind of antivaxxer has no limits. you will have the opportunity to grow!
you're always a brother anti MRNA antivaxxer
It doesn't really bother me$$$$$$$$$
IH-fortunately I’m not addicted to anyone, Open your eyes and stop dreaming.
Open your ears and listen...I'm a stockholder,They are not paid by MRNA
The projected fair value for Moderna is US$124 based on 2 Stage Free Cash Flow to Equity
Moderna's US$86 share price signals that it might be 30% undervalued "minimum"
Then you have to add the filling..
Over the next five years, the Company expects to launch up to 15 new products addressing high unmet needs, to bring up to 50 new candidates into clinical trials and to continue expanding the field of mRNA into new applications
It's written on the wall over here.
iH- shareholder of MRNA ...You're really becoming one of us, kid.
IH- ANTIVAXXER harmless......we are waiting ,your triple hole do not be afraid!!!!!!
The music gave the pioneers strength and courage.
LOL dilution--- repurchased 4.4 million shares in Q2 for a total of $628 million....
The $3 billion share repurchase program announced in February 2022 was completed early in the fourth quarter 2022
good try$$$$$$$
IH- you have to get a hole first
NO. Moderna does not endorse TRC Capital's unsolicited mini-tender offer and recommends that shareholders do not tender their shares in response to TRC Capital's offer because the offer is at a price below the current market value of Moderna common stock and is subject to numerous conditions. Per the terms of the offer, any shareholders who tender (or have already tendered) their shares can withdraw them prior to the expiration of the offer, currently scheduled for 12:01 a.m., New York City time, on October 13, 2023, in accordance with the offering documents, but subject to extension at TRC Capital's discretion.
IHuser - you are a, triple vaccinated RNA
Cause she is living in a dream world?
Safety and Immunogenicity of mRNA-1647, an mRNA-Based Cytomegalovirus Vaccine in Healthy Adults: Results of a Phase 2, Randomized, Observer-Blind, Placebo-Controlled, Dose-Finding Trial(Saturday, October 14??, 2:25-2:35pm ET): Sandeep Basnet, MD, Director of Clinical Development at Moderna, will present data from Moderna’s phase 2 trial of its CMV vaccine.
https://www.modernatx.com/media-center/all-media/blogs/IDWeek
We are the future! One of these players could win in AI -- and in the healthcare market, in general.
All of this may help Moderna solve one of the biggest problems in drug development -- the slow pace. And this could be an enormous victory, resulting in significant earnings growth over the long term.
But Moderna isn't only about AI. The company has more than 40 programs in development and, as mentioned earlier, is set to launch several new products in the coming years.
https://www.fool.com/investing/2023/10/13/1-artificial-intelligence-stock-to-buy-1-to-avoid/?source=eptyholnk0000202&utm_source=yahoo-host&utm_medium=feed&utm_campaign=article
super fast.......
IH- The company has doubled its pipeline in just three years.
All of this means Moderna has the technology and speed to possibly reach the goal of 15 new products in the next few years
Moderna has what it takes to reach its goal from both scientific and financial standpoints. The biotech's platform allows for speed, and it's demonstrated great results so far. And it has the cash to support development.
Those who invest in it today may reap the rewards over time!
than $18 billion in cash$$$$$$$
https://www.modernatx.com/research/product-pipeline
I agree 1000%
Investors once saw Moderna's coronavirus vaccine as a reason to buy the stock, but in recent times, they've seen it as a reason to sell. That's because they've worried about the company's dependence on just one product -- especially a product linked to a pandemic situation.
But here's why we should view Moderna differently. First, even though vaccine demand has declined, it's not going to zero. Moderna has predicted the coronavirus vaccine market will follow that of the flu vaccine market, and if that happens, about half of Americans will go for an annual shot. That should result in recurrent blockbuster revenue for Moderna.
And there's an even bigger reason to be optimistic about Moderna right now. As mentioned above, the company plans on launching up to 15 products in the coming five years. What does this mean financially? Moderna predicts these new products could result in as much as $30 billion in revenue. This well surpasses its coronavirus peak sales of $18.4 billion.
The risk of candidate failure always is possible in the world of biotech and pharma, but even if Moderna succeeds with only a handful of these investigational products, the company's earnings could take off. Meanwhile, Moderna also has been investing in artificial intelligence (AI), a tool that could help its product development become faster and more precise.
Today, Moderna shares trade for about 8.5 times forward earnings estimates, dirt cheap considering the company's future earnings opportunities. And that's why this biotech player is a screaming buy.
MRNA it doesn't need to be pumped-
IHuser----you make me laugh with your jokes
anti-vaxxer from now, sell artichokes at the train station NY.... it is a great fortune fast baby!
‘I Was The First Person To Get The New Breast Cancer Vaccine—And It Completely Changed My Life’
It’s too soon to tell when the vaccine will be available to the public, but I’m sharing my story so that everyone knows about it.
Ohio-native Jennifer Davis received her last dose in 2021 and is still cancer-free
The vaccine changed my life almost immediately.
https://www.womenshealthmag.com/preview/draft/first-triple-negative-breast-cancer-vaccine-recipient-essay?content=88c869a7-94cd-4fba-8de1-c9f841c8357d&type=longform-article
the bean court.....they sell good pills- go buy for the house-
to let you understand----it's just smoke
https://www.reuters.com/legal/pfizer-resolves-promosome-patent-lawsuit-over-covid-19-vaccine-2023-10-05/
no one emerges victorious from the court-
In 4Q23, we anticipate updated Ph2 efficacy data in adjuvant melanoma from the MRK-partnered individualized neotantigen therapy-------
In this version, there are no winners or losers!
LOL $$$ Moderna, Pfizer and BioNTech head to The Hague for first mRNA patent dispute
https://www.juve-patent.com/cases/modern-pfizer-biontech-the-hague-first-mrna-vaccine-dispute/
it's written on the wall-WINNER$
Did Moderna Just Jump Ahead of Rivals in a Potential Billion-Dollar Market-
That's why Moderna's progress on its combined vaccine is something to cheer about, whether the company is one step ahead of its rivals or not.
Meanwhile, Moderna is flush with cash. It reached levels of more than $18 billion at the end of last year and hasn't struggled to move its programs forward
https://www.fool.com/investing/2023/10/06/did-moderna-just-jump-ahead-of-rivals/